Regeneron and Sanofi dosed the first patient outside of the United States with the rheumatoid arthritis drug Kevzara as part of a second global clinical trial assessing the medication as a treatment for COVID-19, the disease caused by the novel coronavirus pandemic.

Sanofi and Regeneron Pharmaceuticals expanded a clinical trial of the companies’ rheumatoid arthritis drug Kevzara as a coronavirus treatment to patients outside the United States.

The number of U.S. coronavirus infections climbed above 86,000 on Friday as New York, New Orleans and other hot spots faced a surge in hospitalizations and looming shortages of supplies, staff and sick beds.

Italian researchers are looking at whether a higher than usual number of cases of severe pneumonia and flu in Lombardy in the last quarter of 2019 may be a signal that the new coronavirus might have spread beyond China earlier than previously thought.

Hundreds of millions of people worldwide were adjusting to once-in-a-generation measures to battle the coronavirus crisis that is not only killing the old and vulnerable but also threatening prolonged economic misery.

Asia reported hundreds of new coronavirus cases – including an American soldier stationed in South Korea – as the United States warned of a pandemic, the disease spread in Europe and Brazil confirmed Latin America’s first infection.

Contract research organization Catalent plans to buy Bristol-Myers Squibb’s manufacturing and packaging factory in Anagni, Italy, used to manufacture oral solid, biologics and sterile products.

The digital HCP engagement provider Physicians Interactive announced two major strategic moves in the past two months, acquiring the HCP content platform Univadis from Merck in October and then rebranding […]